EA201791147A1 - Фармацевтическая композиция, ее получение и применения - Google Patents

Фармацевтическая композиция, ее получение и применения

Info

Publication number
EA201791147A1
EA201791147A1 EA201791147A EA201791147A EA201791147A1 EA 201791147 A1 EA201791147 A1 EA 201791147A1 EA 201791147 A EA201791147 A EA 201791147A EA 201791147 A EA201791147 A EA 201791147A EA 201791147 A1 EA201791147 A1 EA 201791147A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compound
biocompatible nanoparticle
subject
need
compound
Prior art date
Application number
EA201791147A
Other languages
English (en)
Inventor
Маттье Жермэн
Мари-Эдит Мер
Аньес Поттье
Лоран Леви
Original Assignee
Нанобиотикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нанобиотикс filed Critical Нанобиотикс
Publication of EA201791147A1 publication Critical patent/EA201791147A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей комбинацию (i) по меньшей мере одной биосовместимой наночастицы и (ii) по меньшей мере одного носителя, содержащего по меньшей мере одно фармацевтическое соединение, подлежащее введению субъекту, нуждающемуся в таком фармацевтическом соединении, причем комбинация по меньшей мере одной биосовместимой наночастицы и по меньшей мере одного носителя, содержащего фармацевтическое соединение(ия), усиливает эффективность соединения(ий). Наибольший размер биосовместимой наночастицы обычно составляет от приблизительно 4 до приблизительно 500 нм, и ее абсолютная величина поверхностного заряда составляет по меньшей мере 10 мВ (|10 мВ|). Носитель при этом не содержит какого-либо поверхностного стерически стабилизирующего агента. Изобретение также относится к такой композиции для применения для введения фармацевтического соединения(ий) субъекту, нуждающемуся в этом, причем по меньшей мере одна биосовместимая наночастица и по меньшей мере один носитель, содержащий по меньшей мере одно фармацевтическое соединение, следует вводить раздельно субъекту, нуждающемуся в указанном фармацевтическом соединении, обычно с интервалом от более чем 5 мин до приблизительно 72 ч друг от друга.
EA201791147A 2014-11-25 2015-11-24 Фармацевтическая композиция, ее получение и применения EA201791147A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25
PCT/EP2015/077425 WO2016083333A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
EA201791147A1 true EA201791147A1 (ru) 2017-11-30

Family

ID=52013982

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791147A EA201791147A1 (ru) 2014-11-25 2015-11-24 Фармацевтическая композиция, ее получение и применения

Country Status (22)

Country Link
US (1) US10765632B2 (ru)
EP (2) EP4431155A2 (ru)
JP (1) JP6789960B2 (ru)
KR (1) KR102666251B1 (ru)
CN (1) CN107106703A (ru)
AR (1) AR102782A1 (ru)
AU (1) AU2015352685B2 (ru)
BR (1) BR112017010953B1 (ru)
CA (1) CA2968919C (ru)
DK (1) DK3236934T3 (ru)
EA (1) EA201791147A1 (ru)
FI (1) FI3236934T3 (ru)
HK (1) HK1245085A1 (ru)
IL (2) IL252462B (ru)
LT (1) LT3236934T (ru)
MX (2) MX2017006812A (ru)
NZ (1) NZ769187A (ru)
PT (1) PT3236934T (ru)
SG (1) SG11201704219UA (ru)
TW (1) TW201628656A (ru)
UA (1) UA123665C2 (ru)
WO (1) WO2016083333A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014273043B2 (en) 2013-05-30 2019-02-07 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
CN107708668A (zh) 2015-05-28 2018-02-16 纳米生物技术公司 用作治疗性疫苗的纳米粒子

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
KR101133084B1 (ko) * 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) * 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
EP2190411A2 (en) * 2007-08-21 2010-06-02 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011102407A1 (ja) 2010-02-17 2011-08-25 国立大学法人神戸大学 放射線治療剤
EP2898884B1 (en) 2010-03-26 2018-05-09 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
JP5713311B2 (ja) 2010-09-24 2015-05-07 国立大学法人名古屋大学 リポソーム複合体、その製造方法、及びその使用
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
EP2670393B8 (en) * 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
PL2670394T3 (pl) 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
AU2014273043B2 (en) * 2013-05-30 2019-02-07 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
KR20170086638A (ko) 2014-11-25 2017-07-26 나노비오?스 약학 조성물, 이의 제조 및 용도
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações

Also Published As

Publication number Publication date
KR102666251B1 (ko) 2024-05-27
BR112017010953A2 (pt) 2018-02-14
AU2015352685B2 (en) 2020-09-17
TW201628656A (zh) 2016-08-16
JP2017538783A (ja) 2017-12-28
HK1245085A1 (zh) 2018-08-24
CA2968919C (en) 2023-07-18
DK3236934T3 (da) 2024-08-19
JP6789960B2 (ja) 2020-11-25
AR102782A1 (es) 2017-03-22
IL290114A (en) 2022-03-01
EP3236934B1 (en) 2024-05-22
NZ732995A (en) 2021-01-29
MX2021010595A (es) 2021-09-23
KR20170093860A (ko) 2017-08-16
CA2968919A1 (en) 2016-06-02
SG11201704219UA (en) 2017-06-29
LT3236934T (lt) 2024-08-26
EP3236934A1 (en) 2017-11-01
US20170258721A1 (en) 2017-09-14
FI3236934T3 (fi) 2024-07-22
WO2016083333A1 (en) 2016-06-02
PT3236934T (pt) 2024-08-01
IL252462A0 (en) 2017-07-31
US10765632B2 (en) 2020-09-08
NZ769187A (en) 2023-07-28
UA123665C2 (uk) 2021-05-12
BR112017010953B1 (pt) 2024-01-16
IL252462B (en) 2022-03-01
AU2015352685A1 (en) 2017-07-13
CN107106703A (zh) 2017-08-29
MX2017006812A (es) 2018-02-12
EP4431155A2 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
EA201592279A1 (ru) Фармацевтическая композиция, ее получение и применение
EA201791147A1 (ru) Фармацевтическая композиция, ее получение и применения
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX355065B (es) Método y dispositivo para conmutación de cámaras.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
NZ751197A (en) Compounds and methods of treating infections
BR112015019064A2 (pt) métodos de tratamento de melanoma
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
WO2015023691A3 (en) 4-methylumbelliferone treatment for immune modulation
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MY196111A (en) Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
EA201591649A1 (ru) Составы с органическими соединениями
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
SG10201810093PA (en) Pharmaceutical composition for external use